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Anterior Pituitary and TSH* 
P . C . S C R I B A , F . E R H A R D T , H . G . H E I N Z E , K . H O R N , I. M A R S C H N E R , 
C . R. P I C K A R D T 
In 1971, at the Laurentian Hormone Conference, Dr . R E I C H L I N (82) has reviewed the 
evidence in favour of positive feedback regulation of T R H synthesis by thyroid hor-
mones. In the introduction to this outstanding review two factors Controlling d i r e c t l y 
the secretion of T S H were classified as p r i m a r y regulators: 
1. the negative feedback inhibition by thyroid hormones and 
2. the stimulatory effect of T R H . 
Several factors act probably indirectly in the control of T S H secretion (82), including 
the peripheral degradation of T S H , of thyroid hormones and of T R H , the physioche-
mical State of the circulating thyroid hormones, and the pituitary conversion of T 4 to 
T 3 (2,39, 84 a, 89, 98). Even with the additional consideration of thecircadian rhythms 
(14, 66, 67, 94), the role of liver and kidney for the production rates and metabolism of 
T R H , T S H and thyroid hormones ( 3, 10, 13, 33, 50), and of inducable changes of 
T B G levels as one possible alteration of the physiochemical State of the thyroid hor-
mones, it is probably justified to classify these factors as of secondary importance for 
the T S H regulation (82, 85, 87). 
Therefore, this review will concentrate on: 
1. Problems of T S H structure, 
2. recent developments in T S H assays, 
3. deficiency and excess of T R H and 
4. deficiency and excess of thyroid hormones. 
1. Structure and heterogeneity of TSH 
The T S H molecule can be dissociated by the treatment with propionic acid into the 
subunits a and/?. As it has been shown for other glycoproteohormones, the/3-subunit 
carries the immunological and biological confirmation specific for T S H . 
::" Supporten1 by the Deutsche Forschungsgemeinschaft (SFB 51). 
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Radioimmunoassays specific for tbese s u b u n i t s have been developed (6, 47, 48). So 
far, the/3-hTSH radioimmunoassay represents no improvement in terms of specificity 
and sensitivity as compared to the widely used homologous radioimmunoassay for 
hTSH (6). More important, K O U R I D E S et al. (49) have provided evidence that/3-TSH 
subunits are secreted by the pituitary gland(16), but that/3-TSH is not detectable in se-
rum of euthyroids or in patients with Graves' disease, respectively. In addition, the 
elevated levels of ß-TSH in primary hypothyroidism were suppressed by thyroxine 
administration. The finding of a normal regulation of/3-subunit secretion in terms of a 
negative feedback inhibition by thyroxine (49) is of interest w i t h respect to the studies 
of K O H N and W I N A N D (45, 46). These authors have claimed receptors in the retroorbi-
tal tissue capable of binding of bovine T S H , of/3-TSH and of an exophthalmogenic 
product formed by pepsin digestion of bovine T S H , the binding being enhanced by 
y-globulins from patients w i t h Graves' disease. The pathophysiological involvement 
of human ß-TSH or other T S H related factors in Graves' ophthalmopathy remains 
however to be established, if the Observation of K O U R I D E S (49) is conf i rmed. 
In addition to the data on subunits, the earlier work (15) about s/ze h e t e r o g e n e i t y of 
T S H circulating in primary hypothyroidism has been extended by G O L S T E I N and 
V A N H A E L S T (26). Using a radioimmunoassay System for ß-TSH, these authors ob-
served a high molecular weight fraction in the serum of patients with pr imary 
hypothyroidism. Taking a somewhat different approach, E R H A R D T (20) has obtained a 
high molecular weight, T S H immunoreactive preparation from human pituitaries, 
using Sephadex G-100 filtration and subsequently affinity chromatography with se-
pharose linked anti-TSH. The material constitutes 1 - 3 % of the total T S H immunore-
activity in human pituitaries. The Information about this material is still preliminary. 
We know however, that " b i g " T S H is stable upon rechromatography, has an appro-
ximate molecular weight of 200 000 on Sephadex G-200, shows paralellism in the T S H 
radioimmunoassay System ( M R C Standard), has a R N A content below the limits of 
detection (ethidium bromide fluorescence), is stable in 6 M guanidine-HCl p H 5.1, 
0.25% Triton X 100 (37° C , lh) , and shows formation of regulär size immunoreactive 
T S H by trypsin digestion. - It appears therefore likely, that the chapter of T S H struc-
ture and its relation to human pathophysiology is not yet closed. 
2. Recent developments in T S H assays 
The information about the regulation of the secretion of T S H depends obviously on 
the methods available for the determination of T S H . 
Recently, the principle of the highly sensitive c y t o c h e m i c a l assay has been applied to 
T S H determinations, using the induced lysosomal instability (7, 29) . P E T E R S E N repor-
ted in Boston and elsewhere (71), that the T S H level of 0.31 / / U / m l in one normal sub-
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ject was suppressed by daily administrations of 120//g T 3 to 0.17 / /U/ml after 4 days 
and to 0.02//U/ml after 8 days. The latter values are lower than the " T S H " levels of 
0.28//U/ml measured in untreated Graves' disease by this method (71). However, it 
may be too early to aeeept fully the differentiation between T S H and L A T S made me-
rely on the basis of different reaction kinetics in the cytochemical assay (71). A T R H 
Stimulation test increased the T S H level of euthyroid controls from 0.6 to 7.0//U/ml in 
this assay (71). These values are in good agreement with data obtained by the radioim-
munoassay. 
I have to omit any comments on radioreeeptor assays (29), which are at present in de-
velopment or in use in several laboratories (cf. S C H L E U S E N E R ) . - Instead, I should like 
to discuss briefly two aspects of the r a d i o i m m u n o a s s a y for T S H . This method has ra-
pidly become a valuable tool for the clinical judgement of thyroid patients (1, 18, 19, 
28, 29, 70). A vast number of modifications and commercial kits favours its wide-
spread use. However, in addition to the obvious limitations of the T S H radioimmuno-
assay in terms of sentitivity and speeificity, we have to realize, that this method lacks 
adequate interlaboratory comparability. This may be concluded from a recent "Ring-
versuch" or collaborative survey, performed under the auspices of the Thyroid Section 
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The individual means of triplicate determinations of one of 8 unknown samples obtained from 24 partieipa-
ting laboratcries may be read on the abscissas of the histogram. "Wiederfindekurve" Stands for Standards in 
"hormone free" serum. Each rectangle depicts the number of the partieipant and a symbol for the method 
used. The imerlaboratory means (x) and coefficients of Variation (VK) are given for all participants and for 
the group between 5 and 95 % of the Gaussian curvc (mean ± 1.7 SD), respectively (56). 
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As shown in Fig. 1, the better 90% of 24 participants produced a mean of 22.9//L7ml 
for the first of the unknowns, using their own Standard curves. There was a wide Varia-
tion of the single laboratories between 8 and 6 0 / / U / m l , with a coefficient of Variation 
of 64%. Using common Standards in "hormone free" serum (18, 21, 70), the results 
were definitely improved with a more correct mean of 17.3//U/ml and with a reasona-
ble coefficient of Variation of 21.8% between laboratories. Some commercial kits have 
since been improved as a consequence of this study (56). 
The second point, which I would like to discuss, is the need for automation of the ra-
dioimmunoassay for T S H , as for other hormones. We have developed a modular ana-
lyzer System (57), for which the working instruetions for T S H include as the impor-
tant points: Standards i n hormone free serum, " c o l d " preineubation of antibody with 
non - labeled hormone , tracer of rather low specific activity, classical double antibody 
method with discontinuous filtration for b/f Separation etc. (57). - In summary, the 
proper radioimmunoassay for T S H has turned out to be relatively simple, reliable and 
satisfactory for diagnostic purposes. 
a) T R H Stimulation test 
Today, the intravenous T R H Stimulation test has been widely aeeepted as a valuable 
extension (28, 78, 87, 97, 103) of the diagnostic possibilities provided by the T S H ra-
dioimmunoassay. In our hands, the normal ränge of 2.7 to 23.6//U/ml (18, 19) for the 
T S H increment 30 min after injection of 200//gTRH has been satisfactory for diagno-
stic purposes. Numerous and sometimes conflicting reports have been published a-
bout sex and age dependence of the T S H response (51, 68, 97), about other T R H doses 
recommended (5), about the effects of the menstrual cycle and of antiovulatory Stero-
ids (23, 51, 63, 81, 96, 97), and other drugs (17, 83, 102), particularly cortieoids (69), of 
stressful situations and cold (12, 25, 58), of malnutrition respectively anorexia nervosa 
(53, 62, 64), of 2-Br-a-ergocriptine (61), somatostatin (4, 90, 93, 95), Prostaglandins 
(9) and of diseases of the liver and the kidneys (3, 10, 13, 33). However, time does not 
allow to discuss all these data. In general, all these factors rarely diminish the diagno-
stic usefulness of the normal ränge mentioned. 
3 . Deficiency and excess of T R H 
A t first, the regulation of the T S H secretion in t h e a b s e n c e of endogenous T R H has to 
be considered. 
In a series of elegant experiments, R E I C H L I N et al. (82) have shown, that in rats with 
lesions in the hypothalamic thyrotropic area, the sensitivity of the pituitary "thyro-
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stat" towards t h y r o i d hormones is changed. A diminished increase of T S H levels was 
only observed as late as 40 days after thyro idec tomy. In addit ion to this decreased sen-
sitivity of the T S H secretion towards a deficiency in t h y r o i d hormones , the threshold 
for T S H suppression by t h y r o i d hormones was lowered in the rats carrying the h y p o -
thalamic lesions. These experimental data are in agreement wi th the cl inical Observa-
tion of usual ly m i l d h y p o t h y r o i d i s m wi th l o w , but definitely measurable T S H levels in 
patients w i t h hypotha lamic hypopi tu i t a r i sm. It has been repeatedly documented (28, 
60, 74, 75, 78, 87, 92) that T R H Stimulation tests in patients wi th suprasellar disease 
and secondary h y p o t h y r o i d i s m result in normal or supranormal T S H increases. In ad-
d i t ion , we also observed a normal St imulation of T S H secretion by T R H in most pa-
tients w i t h pi tui tary adenoma and secondary h y p o t h y r o i d i s m (74, 75). It w o u l d there-
fore appear, that in pi tui tary tumor patients, the hypothalamic T R H product ion or the 
T R H transport via the portal vessels of the pituitary stalk are more susceptible to d i -
sturbance than the T S H produc ing thyrotrophs of the anterior pituitary themselves. 
T R H was s h o w n to be present i n human cerebrospinal f l u i d , and appears subse-
quently to its injection into the third ventricle of rats in the portal vessels of the p i tu i -
tary stalk (27, 44, 79, 88). This Observation a l lowed the further study of the problem 
mentioned above. F A H L B U S C H and P I C K A R D T (24) compared the normal T S H incre-
ment in patients after intravenous T R H w i t h the T S H response, when 50//g T R H were 
injected into the 3rd or lateral ventricle o n the occasion of diagnostic or therapeutic 
puncture of the ventricles. In " c o n t r o l s " , the T S H response to intraventricular T R H 
was lower as compared to i . v . T R H , and was maximal only at 40 m i n or later. In cases 
wi th tumors in the 3rd ventricle or w i t h pituitary adenomata expanding into the supra-
sellar reg ion, no T S H response was seen after intraventricular T R H , whereas the res-
ponse to i . v. T R H was regularly obtained. Hence, " p o r t a l vessel o c c l u s i o n " (74, 75) 
may wel l be a pathophysiologica l mechanism for " h y p o t h a l a m i c " or secondary h y p o -
pituitarism in cases wi th pituitary adenoma. 
I should n o w like to discuss briefly the effects of prolonged exogenous T R H excess. 
Repeated administrat ion of T R H leads to a rapid declinc of the T S H responses of the 
pituitary (65, 80, 91). This Observation is of some cl inical interest, since oral T R H 
treatmentplays a role in certain Psychiatric diseases, namely depression. Interestingly, 
M A E D A eta l . (54), have recently s h o w n in depressed patients, that single T R H Stimula-
t ion is f o l l owed by an abnormal increase of g rowth hormone , wi th concomitant ly en-
hanced pro lact in responses, but blunted T S H responses. 
Repeated oral administrat ion of 40 mg T R H per day causes only transitory increases 
of T 3 and T 4 , w i t h i n the normal ränge (39, 80, 91). Daily application of 40 mg T R H 
over a per iod of 4 weeks leads f inally to d iminished basal T S H levels and to a blunted 
TSH response to 200//g T R H i . v . (Table 1). This indicates, that the suppressive effect 
of ini t ia l ly ris ing t h y r o i d hormone levels on T S H release is more potent than the s t imu-
lating effect of cont inued oral T R H (40). 
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Table 1. Effect-oi oral T R H application to healthy subjects ( N = 12; 40 mg per day over a period of four 
weeks), from H O R N et al. (39, 40). 
Before T R H After T R H 
Serum T S H basal 2.0 ± 0.8 1.0 ± 0.5:;-
(z/U/ml) A T S H 30 min 8.1 ± 3.0 3.0 ± 1.9* 
Serum T 4 6.2 ± 1.9 6.5 ± 1.8 
(//g/100 ml) 
Serum T 3 112 ± 22 109 ± 32 
(ng/100 ml) 
Significance p < 0.005 
Table 2. T S H and P R L producing pituitary adenoma. 
- Female, 22 y . , enlarged sella. 
- Recurrent goiter and thyrotoxicosis. 
- Galactorrhea-amenorrhea S y n d r o m e . 
- T S H (12 - 29//U/ml) and P R L (200 - 300 ng/ml) refractory to exogenous thyroid hormones and 
to T R H Stimulation (200 //g i. v.). 
- T S H ans P R L suppressed bv bromoeriptine (5 mg p. o.) 
- Identification of "thyrotrophs" and "lactotrophs" evenly distributed throughout the adenoma 
(electronmicroscopy, immunolluorescence). 
H O R N , K. et al., Proceed. Int. Thyroid Conf . , Boston, 1975 (40). 
The fact, that continued oral application of excess T R H failed to induce hyperthy-
roidism, may be taken as another strong argument against any hypothalamic form of 
thyrotoxicosis. 
Finally, the effect of primary pituitary T S H excess should be briefly considered. A 
T S H producing adenoma of the pituitary gland is a rare finding; I am only aware of 
three well documented cases published in the literature (22, 31, 52). Recently we had 
the opportunity to study a patient with a so far unique adenoma producing both, T S H 
and prolactin concomitantly (40). Table 2 summarizes the findings in this patient. It 
may be concluded, that the "thyrotrophs" of this T S H producing adenoma lack the 
adequate reeeptor or sensitivity for negative feedback inhibition by thyroid hormones 
and for T R H Stimulat ion, respectively. This corresponds to other hormonally active 
pituitary adenomata, in which the phenomenon of "reeeptor degeneration" (99) has 
been demonstrated. 
4. Deficiency and excess of thyroid hormones 
The remainder of this contribution will be devoted to regulatory T S H increases and 
decreases by the thyroid hormone negative feedback mechanism. Obviously, most of 
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the diagnostic information obtained by T S H radioimmunoassay is derived from pa-
tients with primary thyroid disease, since it has been realized, that feedback alteration 
of the T S H secretion currently represents the most sensitive indicator for lack or excess 
of thyroid hormones (72, 82, 87). Innumerous studies dealing with different aspects of 
this field have been published and cannot be reviewed within the limitations of time. 
Also, the interesting questions of intrapituitary conversion of T 4 to T 3 , of pituitary 
preferential T3-receptors, and of the relative contributions of T 4 and T 3 in the circula-
tion to the negative feedback regulation of T S H secretion (2, 39, 84a, 89, 98) have to be 
left to the discussion. Instead, we thought it worthwhile to discuss briefly and as a cli-
nical example some problems related to endemic goiter. Nontoxic goiter is known to 
be the most frequent thyroid disease in the Federal Republic of Germany, which has 
recently again been shown to be as a whole an area of endemic goiter (41) and of sub-
stantial iodine deficiency (30, 86). 
D e f i c i e n c y i n t h y r o i d h o r m o n e s is known to give rise to elevated basal T S H levels, an 
Observation which may be further elucidated by the Observation of increased T S H re-
sponses to i . v . T R H Stimulation tests. I should like to leave possible controversies a-
bout the term "subclinical hypothyroidism" (68, 72) to the discussion. I would rather 
emphasize, that T S H radioimmunoassays have already been used for Screening pro-
grams e. g. for neonatal hypothyroidism (36). 
Approximately 20% of the iodine deficiency goiter patients of Munich (72, 73, 77) 
were shown to display an increased T S H response to T R H Stimulat ion. This increase 
above the Upper limit of normal, usually shown in a logarithmic scale, is quite remark-
able in some patients. This finding has been confirmed for Essen and Göttingen (100). 
The elevated T S H levels are obviously not related to the tendencies of these patients 
towards low-normal or slightly decreased T 4 levels and towards normal or slightly ele-
vated T 3 levels (Fig. 2). The latter phenomenon is known as preferential T 3 secretion in 
iodine deficiency states (37, 39, 72). The elevated T S H secretion in 1/5 of the goiter pa-
tients may be interpreted as evidence for 
1. slight thyroid hormone deficiency in this group and/or 
2. a phase of further growth of the already enlarged thyroid. 
The fact, that 80% of our patients have normal T S H responses despite their thyroid 
enlargement, may be interpreted als indicative for 
1. no actual progression of their goiter and/or, 
2. if there is further goitral growth, this might indicate an enhanced thyroid sensitivity 
to normal circulating levels of T S H as proposed by B R A Y (8). 
Interestingly, the thyroidal adaptation to iodine deficiency in terms of an elevated se-
rum T 3 / T 4 ratio is reversible without measurable alteration of the T S H secretion. 
H O R N et al. (38) have shown, that administration of 200^g iodine per day as potassium 
iodide tablets over a period of four weeks reduced the elevated T 3 / T 4 ratio towards 
normal. Since the mean basal T S H levels and the T S H responses to 200//g T R H i . v. 
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• = Blande Struma 
\ TSH normal 
• = Blande Struma 
A TSH A TSH erhöht 
u,E/ml A = Rezidivstruma 
Fig. 2. T o t a l s e r u r n TA and as related t o t h e T S H response (A T S H 30 m i n ) t o 2 0 0 //g T R H i . v. 
'Blande Struma" is synonymous with nontoxic goiter, "Rezidivstruma" with recurrent goiter after Opera-
tion (37, 39, 73, 78). 
were the same prior to and after 4 weeks on 200/ /g iodine per day, it was concluded, 
that this may represent an example of thyroidal autoregulation (42) . 
The treatment of goiters with T S H suppressive doses of thyroid hormones may rea-
dily be controlled by T R H Stimulation tests and radioimmunoassay for T S H (77, 78 , 
103). 
Finally, we have to focus on the impact of t h y r o i d h o r m o n e excess on the T S H secre-
tion. Again, T S H suppression and, even more, the failure of T R H to induce a T S H 
response is widely aeeepted as a very sensitive tool for the diagnosis of endogenous or 
exogenous excess of thyroid hormones. Notedly, the sensitivity of this feedback Inhi-
bition carries the general diagnostic disadvantage, that T S H suppression may persist 
for prolonged intervals after e. g. sufficient and successful treatment of hyperthyro-
idism. The latter Observation has been described by V O N Z U R M Ü H L E N in 1971 (103) 
and was confirmed repeatedly (11 , 3 2 , 84 , 104). 
Selecting the endemic goiter patients again for this consideration, I should like to 
draw the attention to what was called the "functional cycle of the autonomous adeno-
ma" by P I C K A R D T et al. (76 , 85) . This coneept was derived from observations of nume-
rous patients at different stages of the disease, extending the work of M I L L E R et al. (59) . 
Fig. 3 describes schematically the development of an adenoma, its poorly understood 
acquisition of autonomy, the gradual addition of toxicity with the concomitant in-
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Fig. 3 F n n c t i o n a l c y c l e o f t h e a u t o n o m o u s a d e n o m a . 
After P I C K A R D T , C . R. et al., Dtsch. med. Wschr. 9 8 : 152 (1973). 
crease of thyroid hormones and decrease of the T S H secretion and response to T R H , 
and finally the possible spontaneous remission. One has of course only rarely the occa-
sion to follow this cycle throughout all stages in one single patient. However, sponta-
neous transitions have been observed in between all stages depicted. The most fre-
quently observed transition is certainly from stage 2 , which is an autonomous nodule 
with normal T 4 and T 3 and positive T S H response to T R H Stimulation - usually called 
compensated autonomous adenoma - to stages 3 or 4 with normal or elevated T 4 and T 3 
and suppressed T S H , which is commonly called decompensated autonomous adeno-
ma. The latter transition has been regularily observed in a somewhat courageous study 
of M A H L S T E D T and J O S E P H (55) , when practically all compensated autonomous ade-
noma ta in patients were converted to "decompensated" ones by contrast media used 
for cholecystography. T R H Stimulation tests show easily in the patients with decom-
pensated autonomous adenoma, that the T S H secretion is in fact suppressed, as it was 
correctly predicted by the earlier indirect methods of nuclear medicine. The existence 
of suppressed paranodular thyroid tissue around the hot nodule can be documented by 
simple palpation or by 9 9 m T c scintigraphy with increased sentitivity (35 , 101) , avoi-
ding the disadvantages of a T S H Stimulation test, which may be only justified if con-
comitant cold nodules have to be depicted. The hazards of the exogenous T S H Stimu-
lation test consist mainly in the sometimes dangerous elevation of the thyroid hormo-
nes (34) by Stimulation of the paranodular tissue and of the hot nodule itself (43) , 
which is thus not "autonomous" in this respect. 
In conclusion, I should like to express my hope, that it was not against the intentions 
of the convenors, that the emphasis of this presentation was put on clinical aspects. 
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Discussion 
S C H L E U S N E R raised the question of the binding of the T S H /3-subunit to thyrocyte 
membrane preparations. W O L F F pointed out that bovine /3-subunit binds to bovine 
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membranes at about 8 % of the T S H potency (Bethesda). The more complicated the 
stimulated cell funetion, the more intact the tissue is, the less active is theß-subunit. 
V O N Z U R M Ü H L E N suggested to study the question of the biological acticity of the 
"big T S H " originating from human pituitaries. Reference was made by R A L L to the 
studies of W E I N T R A U B and R O S E N , in which they looked at tumors, bronchogenic Car-
cinoma, mostly, that produced ectopic T S H . They could isolate different clones of 
cells from these tumors, and some of the clones would produce normal T S H , the al-
pha-beta material, some would produce just the alpha and some would produce just 
the beta. A n d this gets back to the fundamental question as to whether they are synthe-
sized as separate Polypeptide chains and combined then in an entirely physical way? 
The mentioned data tended to suggest the latter, which makes then the "big T S H " a 
difficult protein to swallow. 
However, work from R Y A N ' S group suggested, that large molecular weight gonado-
tropins might consist of one/3-subunit and several a-subunits. Further workis needed 
to clarify these important questions. 
C R O O K S reported a study of pregnancy goiter and of normal controls from Iceland 
and Scotland, respectively, where the controls had the same frequency of thyroid anti-
bodies. The Icelandic normal population has twice the level of plasma inorganic iodine 
of the controls of Scotland. The normal T S H levels in Iceland are lower, with a narrow 
ränge normal distribution, as compared to Scotland, where the normal ränge of T S H is 
spread widely yet still normally distributed. 
This raised the question what actually regulates T S H at different levels in these two 
populations? A rather general ans wer would be, that the sum of interactions of ante-
rior pituitary reeeptors for T 3 , T 4 and possibly triac with the intracellular concentra-
tions of these hormones at the site of the (nuclear) reeeptor should be the relevant 
event. There is a modulation by the TRH-thyrotroph System, but thyroid hormones 
are probably the most important factor. 
Rare cases of evident hyperthyroidism with positive T S H response to T R H Stimula-
tion were reported from L o o s , U l m and S T A U B , Basel, the incidence being probably 
very low and the mechanism still obscure. 
P I N C H E R A commented a study from Pisa. Patients with a completed course of anti-
thyroid treatment showed an inverse relationship between the T S H response to T R H 
and the serum T 3 and T 4 , respectively, whereas there was no correlation to the sup-
pression test. However, the T R H Stimulation test was of no predictive value for the 
question of relapse of hyperthyroidism. This was supported only in part from Dr . 
E M R I C H , Göttingen, where in most but not in all patients treated for hyperthyroidism 
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follow up studies showed coincidence of negative suppression tests and negative T R H 
Stimulation tests and vice versa. The persistance of negative T R H Stimulation tests in 
the presence of low T 4 and T 3 after antithyroid treatment might also be a funetion of 
the duration of the preexisting thyrotoxicosis. 
P I N C H E R A raised the question of the T 4 and T 3 response to T R H Stimulation in goiter 
patients. L E M A R C H A N D - B E R A U D gave comments to this question. In Switzerland 
(Lausanne), endemic goiter is aecompanied by normal responses of T 4 and T 3 levels to 
T R H . In addition, the T S H response is usually normal and sometimes decreased. 
These findings are of interest in view of the installed iodine Prophylaxis in Switzerland. 
As supported from K O U T R A S Athens, the T S H levels or responses are apparently the 
higher, the more severe the iodine deficiency is. In addition, high proportions of goiter 
patients with positive thyroid antibody titers tend to cause supranormal T S H levels 
(Helsinki, Brüssels). From Brüssels, further cases were reported with latent thyroidi-
tis, with hypersecretive thyrotrophs and with high biological, but normal immunolo-
gical T S H activity. A l l discussors agreed to treat patients with elevated T S H levels by 
administration of thyroid hormones. 
W O L F F raised the question of the T R H test in patients under lithium therapy. L A M -
BERG commented on this. In a systematic study from Helsinki no changes were obser-
ved, neither in the T S H response to T R H nor in thyroid hormone levels. Studies from 
Athens and Freiburg however tend to show, that under lithium therapy some patients 
go through initially low T 4 and T 3 levels and that patients with lithium goiter are usu-
ally "hypothyroid" . 
O P P E N H E I M E R questioned the role of T R H in the practice of medicine in terms of 
diagnostic use and socioeconomical implications. The author of the above paper repea-
ted the view, that T R H Stimulation tests are at present the most sensitive tool for dia-
gnosis of lack or excess of thyroid hormones, even with the drawback of persisting 
suppression after thyrotoxicosis, that they allow to choose a dose of thyroid hormone, 
which will suppress the T S H response for instance in the treatment of non-toxic goi-
ter, or which alternatively normalizes the T S H response in substitutive therapy for 
myxedema. In addition, the facilitation of the diagnosis of an autonomous (toxic) ade-
noma was stressed. Finally, the T R H test is economical in terms of patients and doc-
tors timeif compared with repeated radioiodine uptake tests or suppression tests e. g., 
and that the actual costs for the radioimmunoassays of T S H can be lowered by auto-
mation. This view was challenged from G R E E R , and supported from H Ö F E R . I n sum, 
the T R H test is used for practical diagnostic purposes in some places, and it is conside-
red a research procedure in others. 
